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Abstract
The objective of this study was to examine B-cell CLL/lymphoma 6 (BCL6) expression in human eutopic endometrium across the
menstrual cycle in women with and without endometriosis and to establish a cutoff for future studies. This design was a series of
case–control studies in tertiary University teaching hospitals. We examined BCL6 expression by messenger RNA and immu-
nohistochemically in prospectively collected samples in both the proliferative (P) and the secretory phases. BCL6 is minimally
increased in the mid-secretory phase of the menstrual cycle compared to the P phase in normal patients. BCL6 protein expression
was significantly higher in the secretory phase of patients with endometriosis (n ¼ 29) versus fertile controls without endo-
metriosis at laparoscopy (n¼ 20; P < .0001). Normal fertile controls (n¼ 28) recruited for endometrial biopsy also had low levels
of secretory phase BCL6 expression compared to women with unexplained infertility (UI; n ¼ 119). A receiving–operator
characteristic analysis of these data revealed an area under the curve of 94% (95% confidence interval 85%-100%; P < .0001) with
an HSCORE cutoff of 1.4 to differentiate cases with and without endometriosis. Using this cutoff value, BCL6 was positive in 88%
of cases with UI. Laparoscopic examination of a subset of 65 patients confirmed abnormalities in 98% of cases; 61 (93.8%) were
found to have endometriosis, 3 (4.6%) with hydrosalpinx, and 1 (1.5%) with a normal pelvis. These data suggest that BCL6 is a
promising candidate as a single diagnostic biomarker for detection of endometriosis in women with otherwise UI and may be
associated with endometrial dysfunction, including progesterone resistance.
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Introduction
The human endometrium is a dynamic, hormone-responsive
tissue that undergoes repetitive, cyclic proliferation, differen-
tiation, apoptosis, tissue breakdown, and repair to support its
major function of regulating embryo implantation. These
dynamic changes are orchestrated, directly and indirectly, by
the sex steroids estrogen and progesterone and mediated by
paracrine factors including classical immune system cytokines
and chemokines.1
According to the American Society for Reproductive Med-
icine, unexplained infertility (UI) is estimated to represent 5%
to 10% of couples with infertility.2 Unexplained causes account
for at least 40% of recurrent pregnancy loss.3 Endometriosis is
the predominant finding in UI, when diagnostic laparoscopy is
performed.4-6 While laparoscopy is an important part of the
workup for women with subfertility, this intervention is inva-
sive, expensive, and not readily available to all women. There-
fore, a diagnostic test for endometriosis would be a valuable
tool for this population of women with otherwise UI.
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Endometriosis is a common, inflammatory condition7 and a
leading cause of pain and infertility, affecting an estimated 176
million women worldwide.8,9 Large differences in reproductive
hormonal cycles between human and animal models (other than
old-world primates), reproductive tract anatomy,andmechanisms
governing endometrial function at embryo implantation have
impeded progress in understanding the effects of endometriosis
on human fertility. Further, the lack of validated biomarkers to
screen for or diagnose endometriosis or to monitor recurrence of
this disease accounts in part for the long delay in diagnosis.10
Endometriosis is associated with biological changes in the
eutopic endometrium, which includes increased endometrial
proliferation and inflammation, decreased apoptosis, altered
cellular immunity, and diminished responses to progesterone
also known as progesterone resistance.11 The tumor suppressor
protein p53 is significantly decreased in endometriosis.12
Expression of p53 is specifically inhibited by B-cell CLL/lym-
phoma 6 (BCL6), a nuclear gene repressor associated with
cellular proliferation.13,14 BCL6 is upregulated by Signal trans-
ducer and activator of transcription 3 (STAT3)15 which we
recently reported as phosphorylated (pSTAT3) in eutopic endo-
metrium of women with endometriosis compared to those with-
out this disease.16 Like pSTAT3,17,18 BCL6 is overexpressed in
different types of cancer,19-22 while p53 is decreased.23 These
relationships may account for the proliferative and inflamma-
tory phenotype of endometriosis. Further, as a gene repressor,
BCL6 may account for progesterone resistance through
decrease in known progesterone-mediated factors, including
the Indian Hedgehog pathway involving COUP transcription
factor 2 (COUP-TFII).24,25
There is little information available on BCL6 expression in
endometrium of humans. The objectives of this study were to
investigate BCL6 expression in human eutopic endometrium
across the menstrual cycle in women with and without proven
endometriosis and to evaluate the potential for BCL6 protein
immunostaining as an endometriosis biomarker by describing
the differences between populations, to establish an immunos-
taining cutoff to best define normal versus abnormal, and to
apply the test to a large group of women with UI before under-
going laparoscopy as a prevalidation of BCL6 testing.
Materials and Methods
Study Design and Settings
This is a case–control study derived from prospectively obtained
samples at the University of North Carolina (UNC) at Chapel
Hill and from Greenville Health System (GHS), Greenville,
South Carolina, between January 2002 and December 2013.
Additional fertile controls who underwent laparoscopic tubal
ligation were prospectively obtained from the Institute for
Maternal and Child Research, Santiago, Chile, were studied.
Participants
The study was approved by the institutional review committees
at both UNC–Chapel Hill and GHS. Participants were given
written consent for collection and use of their tissues. Three
different populations were used in this study: (1) endometrium
from paid volunteers who served as normal fertile controls
(endometrial tissue from controls); (2) endometrium obtained
from women with infertility and or pain who underwent laparo-
scopy (women with and without endometriosis and BCL6
expression in eutopic endometrium); and (3) endometrium
obtained in urinary luteinizing hormone (LH)-timed, mid-
secretory (MS) phase of the menstrual cycle from women with
UI (endometrial sample of women with UI).
Endometrial tissue from controls. Endometrial samples for normal
controls were derived from prospective studies at the UNC at
Chapel Hill described elsewhere.26 Briefly, women were
recruited as paid volunteers to undergo endometrial biopsy in
the proliferative (P) phase or in LH-timed sampling in the early
secretory (ES), mid-secretory (MS), and late secretory (LS)
phases. None had pain or infertility or signs or symptoms of
endometriosis. Endometrial samples were obtained with
Pipelle endometrial curette (Cooper Surgical, Trumbull, CT)
across the menstrual cycle phase determined by urinary LH
surge monitoring (Ovuquick; Quidel, San Diego, California).
Samples were classified as P, ES (ES—LH surge þ 1 to 5
days), MS (MS—LH surge þ 6 to 10 days), or LS phases
(LS—LH surge þ11 to 14 days). Those with body mass index
(BMI)  30, who took medications known to affect reproduc-
tive hormones during the previous 3 months, and those who had
known anatomic or functional reproductive tract abnormalities
were excluded. Samples were included only if endometrial
dating agreed with the cycle day of the biopsy (+2 days).
A second set of fertile controls included women with prior
fertility undergoing diagnostic laparoscopy for tubal ligation
(n ¼ 18) or fibroids or uterine prolapse (n ¼ 2). Laparoscopic
inspection showed no endometriosis, and each patient had a
luteal phase endometrial biopsy at the time of surgery. None
had received hormone therapy for at least 3 months.
Women with endometriosis. Endometrium was obtained by
Pipelle endometrial biopsy from women who underwent
laparoscopy for pelvic pain and/or infertility. The biopsy was
obtained prior to or at the time of surgery. Endometrial samples
were obtained from both P and secretory phases of the men-
strual cycle, depending on where that patient was at the time of
surgery. Secretory phase samples were assigned as ES, MS, or
LS based on the date of the last menstrual cycle and by histo-
logical dating according to the Noyes criteria.27 Endometriosis
was visually confirmed by laparoscopy according and stage
assigned based on the Revised American Society for Repro-
ductive Medicine criteria.28 Those who refused endometrial
biopsy were excluded.
Endometrial samples of women with UI. A separate set of MS
endometrial samples was prospectively obtained as part of an
infertility workup in women with UI (n ¼ 119). For the pur-
poses of these studies, UI diagnosis required only that the
patient had normal ovulatory menstrual cycles (25-35 days),
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no history of pelvic infection, and a partner with normal sperm
count and motility according to the World Health Organiza-
tion.29 Fallopian tube patency was determined by hysterosalpin-
gography or at the time of a laparoscopy by chromopertubation.
Exclusion criteria included age 40, history of pelvic infection
or pelvic inflammatory disease, polycystic ovary syndrome, or
the presence of fibroid tumors.
Variables/Data Sources/Measurement
Expression of BCL6, either by reverse transcriptase polymer-
ase chain reaction (RT-PCR) or by immunohistochemistry,
using the 2DCt method and the HSCORE, respectively, were
the outcomes analyzed. Details of the measurement are
described in the RNA isolation and quantification and immu-
nohistochemistry sections. Women with endometriosis, with
UI, and controls were the groups analyzed and compared.
Parity was a potential confounder, and separate statistical
analysis was used to verify the effect of parity on BCL6
expression.
Cell Separation
Endometrial samples obtained from normal controls during
the secretory phase of the menstrual cycle were washed with
Opti-mem media supplemented with fetal bovine serum
(FBS) and antibiotics (10 000 IU/mL penicillin, 10 000 IU/
mL streptomycin; Life Technologies, Grand Island, New
York). Tissue was recovered via centrifugation and incubated
with collagenase-containing medium (phenol red-free Dul-
becco Modified Eagle Medium/F12, 0.5% collagenase I,
0.02% DNase, and 5% FBS). Cell types were separated as
described previously.30
RNA Isolation and Quantification
Total RNA from endometrial frozen tissue was isolated using
RNAqueous-4 PCR kit (Ambios, Austin, Texas), quantification
was performed using RiboGreen (Invitrogen, Carlsbad, Cali-
fornia, and complementary DNA was synthesized as described
previously.31 Reverse transcription conditions were 25C for 5
minutes, 42C for 15 minutes, and 95C for 5 minutes. Quan-
titative real-time RT-PCR was performed on total RNA using
primer-probe sets specific for BCL6 (Gene Expression Assays;
Applied Biosystems (Foster City, CA)—assay HS00153368),
and expression was normalized with the constitutively
expressed gene, peptidylprolyl isomerase A (PPIA;
Hs99999904 ml; Applied Biosystems). PPIA was chosen after
a validation of 12 housekeeping genes in endometrium as
described before.32 Real-time PCR employed Brilliant II
QPCR Master Mix (Stratagene) in a total reaction volume of
20 mL and was performed on a Stratagene MX3000P machine
(Stratagene, La Jolla, CA) using 40 two-step cycles (95C for
25 seconds, followed by 60C for 1 minute). The RT-PCR data
were analyzed using the 2DCt method, as described.33
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue blocks were sectioned
at 4 mm. Slides were stained with hematoxylin–eosin, and con-
secutive sections stained with ready-to-use antibodies against
BCL6 (clone LN22; Leica Microsystems, Buffalo grove, Illi-
nois). Immunohistochemistry was performed on an automated
system by a certified Pathology Laboratory at GHS (Pathology
Associates, GHS, Greenville, South Carolina) using the Bond
immunostainer platform (Leica Microsystems). Following expo-
sure to the horseradish peroxidase-conjugated streptavidin sub-
strate, positive immunoreactivity (red precipitate) was detected
using the Vectastain Elite DAB kit (Vector Laboratories, Bur-
lingame, CA). Negative control sections included P phase endo-
metrium from normal fertile individuals, and positive controls
included lymph node sections. The semiquantitative assessment
of expression was made using the HSCORE (0-4), calculated
using the following equation: HSCORE ¼ P Pi (i þ 1)/100,
where i ¼ intensity of staining with a value of 1, 2, or 3, (weak,
moderate, or strong, respectively) and Pi is the percentage of
stained epithelial cells for each intensity, varying from 0% to
100%. The use of HSCORE has been previously as a semiquan-
titative assay for immunohistochemical staining.34
The use of an automated system for immunostaining
reduced a potential bias in immunohistochemical analysis, read
by a gynecologic pathologist (D.P.S). Certified Board gynecol-
ogists with experience in endometriosis diagnosis were respon-
sible for the laparoscopies, reducing detection bias.
Study Size, Quantitative Variables, and Ethical Approval
The institutional review boards at the UNC and GHS approved
all protocols for collection and use of human samples. Written
consent was obtained from each patient prior to enrollment.
Sample size for BCL6 immunohistochemical analysis was cal-
culated according to the literature35 using the following for-
mula: n ¼ [(za þ zb)2 . 2 . s2]/d2, where alpha error (za) as
0.02, power (zb) of 0.9, an estimated standard deviation (s) of
BCL6 of 0.2, and a difference (d) between means of both
groups (endometriosis vs control) of 0.5 points in an HSCORE
scale that ranges from 0 to 4. The variance (s2) was obtained
from a pilot study with 15 cases of normal endometrium. These
figures yielded a minimum of 4 cases in each group because the
standard deviation of BCL6 was low, that is, 0.2. Sample size
for receiving–operating characteristics (ROC) curve was cal-
culated as described,36 considering a za as 0.05, power (zb) of
0.9, an expected accuracy of 95%, and a ratio of 2:1 of patients
with endometriosis and without endometriosis. These figures
yielded a sample size of 20 and 10 patients with and without
endometriosis, respectively. Gaussian distribution was verified
using the D’Agostino and Pearson omnibus normality test. The
Student t test was used to compare means. If normality of the
data were not confirmed, the Mann-Whitney U or Kruskal-
Wallis nonparametric tests were used to compare medians.
Dunn correction for multiple comparisons was used as a post
hoc test in Kruskal-Wallis test. Statistical analysis was
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performed using GraphPad Prism version 6 for Macintosh
(GraphPad software, Inc, San Diego, California). Analysis of
covariance (ANCOVA) was used for adjusting HSCORE
between groups using an online calculator (http://vassarstats.
net/ancova2L.html), since parity in controls and cases (endo-
metriosis) was significantly different. The ANCOVA online
calculator was used for statistical analysis.
Results
Participants and Descriptive Data
Demographic data of the studied populations are shown in
Tables 1 and 2. Among the variables, BMI and parity were
higher in the fertile control groups compared to those with
endometriosis at laparoscopy (Table 1; P < .001 and P < .0001,
respectively). The fertile control group had a higher parity
than the UI group (Table 2; P < .001).
Expression of BCL6 in Endometrial Biopsies From
Controls
Whole endometrial messenger RNA (mRNA) analysis using
quantitative RT-PCR for BCL6 over the menstrual cycle
revealed that BCL6 is minimally increased in the MS phase
compared to the P phase (P ¼ .02, Kruskal-Wallis with Dunn
post hoc test; Figure 1A). Immunohistochemical analyses of
BCL6 expression in normal eutopic endometrium across the
menstrual cycle (Figures 1B and 2A-D) were similar to those
found with RT-PCR. No expression was noted in the P phase,
and staining across the secretory phases was similar, maintain-
ing low levels of expression across the ES, MS, and LS phases,
with none achieving statistical significance. The differential
expression of BCL6 predominantly in endometrial epithelium
was demonstrated by RT-PCR in enzymatically separated
endometrial glands and stroma from the secretory phase (P ¼
.005, Mann-Whitney U; Figure 1C).
Expression of BCL6 in Endometrial Biopsies From Fertile
Controls and Infertile Women With Endometriosis
Significantly higher BLC6 mRNA levels were seen in the
secretory phase of infertile women with endometriosis
(P ¼ .001, Kruskal-Wallis with Dunn post hoc test;
Figure 1D). Secretory phase BCL6 was also higher in the P
phase in women with endometriosis (P ¼ .01, Kruskal-Wallis
with Dunn post hoc test; Figure 1D). In the 2 fertile control
groups, average BCL6 expression was low in both the groups.
Women with proven fertility but no laparoscopy had elevated
BCL6 levels in 2 (7%) cases. In women with prior fertility and
laparoscopy showing no endometriosis, 3 (13.6%) of 22 had
high levels of BCL6 expression (Figure 1F).
Based on these results, comparison of BCL6 was standar-
dized to the MS phase in women undergoing laparoscopy.
BCL6 immunohistochemical expression was significantly
higher in patients with endometriosis at laparoscopy
(n ¼ 29), compared to women without endometriosis (n ¼ 20;
P < .0001, Mann-Whitney test; Figure 1F). Receiving–operator
characteristic analysis revealed that the area under the curve was
96% (95% confidence interval [CI] 0.908-1.01; P < .0001) and
an HSCORE cutoff of 1.4 (Figure 1E—dotted line).
Women With UI
Using this ROC-defined HSCORE cutoff, we determined
BCL6 expression in 119 women with UI. All samples were
analyzed by immunohistochemistry for BCL6 expression in
urinary LH-timed, MS phase biopsies of eutopic endometrium.
BCL6 was significantly overexpressed in cases of UI compared
to controls (P < .0001—Mann-Whitney U test; Figure 1F).
Based on the preestablished HSCORE cutoff, 105 of 119 with
UI tested positive for BCL6 (88%; 95%CI 81%-92%). Of the
105 patients, 65 underwent subsequent laparoscopy with find-
ings of endometriosis in 61 (93.8%), hydrosalpinx in 3 (4.6%),
and a normal appearing pelvis in 1. In the cases with





Cases (n ¼ 29) P Value
Age, mean (SD) 34.2 (6.6) 32.4 (4.5) .27a
Body mass index,
mean (SD)
31.6 (4.4) 23.3 (4.8) <.001a
Parity <.0001b
Median (range) 2.4 (2-5) 0 (0-2)
n/total (% parous) 20 (100%) 6/29 (20.7%)
Endometriosis stage, n (%)c
I/II 21 (72)
III/IV 8 (28)
Abbreviation: SD, standard deviation.
a Student t test.
b Mann-Whitney U test.
c Pathology report was obtained from 24 of 29 cases.
Table 2. Demographics of Unexplained Infertility (UI) and Fertile
Controls for BCL6 Testing.
Characteristic
Control
Group (n ¼ 28)
UI Group
(n ¼ 119) P Value
Age, mean (SD) 32.77 (2.6) 33.23 (4.2) .59a
Body mass index,
mean (SD)
25.6 (4.7) 25.3 (5.5) .08a
Parity <.0001b
Median (range) 2 (1-3) 0 (0-3)
n/total (% parous) 28/28 (100%) 22/119 (18.4%)
Race, n (%) .3c
Caucasian 23 (82.1%) 106 (89%)
African American 2 (7.4%) 5 (4.2%)
Other 3 (11.1%) 8 (6.7%)
Abbreviation: SD, standard deviation.
a Student’s t test.
b Mann-Whitney U test.
c Chi-square for trend.
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hydrosalpinx, tubal patency had not been established prior to
surgery, rather was determined during surgery by chromoper-
tubation. We compared these cases with UI to normal, fertile
volunteers with LH-timed, MS phase in which 2 (7.1%) of 28
tested positive for BCL6. In another set of laparoscopically
studied fertile controls, 3 (13.9%) of 22 were positive for BCL6
staining (both P < .001).
Other Analyses
Analysis of covariance was performed to identify whether par-
ity between groups had influence on BCL6 expression in the
comparison between infertile women with and without endo-
metriosis, and in the prospective cohort of fertile women and
women with UI. Levene test of equality of error variances was
0.4 and 0.5, respectively. After running ANCOVA, parity was
adjusted, and the P value the between groups was <.0001 in
both analyses, confirming the significant difference, despite the
parity difference between the groups.
Discussion
This study provides the first detailed examination of BCL6
expression in the human endometrium throughout the men-
strual cycle, in women with and without endometriosis.
BCL6 protein expression has a nuclear localization, and both
mRNA and protein expressions are increased in endometrial
epithelium of infertile women with endometriosis in the
secretory phase.
It is known that endometriosis is an inflammatory
condition7,37 and that inflammatory cytokines are associated
with signs of progesterone resistance.25 Inflammatory cyto-
kines, such as interleukin 6 (IL-6), are elevated in peritoneum
and in plasma of women with endometriosis.38,39 We
Figure 1. B-cell CLL/lymphoma 6 (BCL6) expression at different states. A, Quantitative RT polymerase chain reaction (RT-PCR) levels of BCL6
messenger RNA (mRNA) in whole normal endometrium evaluated each cycle phase, determined by cycle day and urine luteinizing hormone
(LH) detection. Mid-secretory levels of BCL6 were significantly higher compared to proliferative phase (P ¼ .02, Kruskal-Wallis with Dunn post
hoc test). B, HSCORE values based on immunohistochemical expression of BCL6 across the menstrual cycle in normal women. No statistical
difference was found among groups (Kruskal-Wallis). C, Quantitative RT-PCR levels of BCL6 mRNA in separated stromal and epithelium cells
from whole endometrial tissue. A higher level of expression was found in the epithelial compartment (P ¼ .0005, Mann-Whitney U test). D,
Quantitative RT-PCR levels of BCL6 mRNA obtained from proliferative and secretory phase in women with and without endometriosis.
Significant difference was found between secretory phases of both groups and between proliferative and secretory groups of endometriosis
(P ¼ .001 and 001, respectively—Kruskal-Wallis with Dunn post hoc test). E, Receiving–operator characteristic (ROC) analysis comparing
laparoscopically proven endometriosis to fertile women without endometriosis at the time of laparoscopy. The dotted line represents the
ROC-determined HSCORE cutoff of 1.4. F, Immunohistochemical expression (HSCORE) of BCL6 between fertile controls (Fertile) and fertile
women without endometriosis at laparoscopy (L/S Controls) compared to those with endometriosis at laparoscopy (L/S E’osis; P < .0001, Mann-
Whitney). A further comparison was made between immunohistochemical expression (HSCORE) of BCL6 between women with unexplained
infertility (UI) and both fertile control groups (P < .0001, Mann-Whitney U test). All boxes in each graph represent the median levels of mRNA of
expression or HSCORE.
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previously showed that IL-6 increases pSTAT3 (activated) in
the endometrium of women with endometriosis,16 and other
authors demonstrated that STAT3 upregulates BCL6.15 There-
fore, overexpression of BCL6 in eutopic endometrium of
women with endometriosis is both logical and consistent with
these known changes in eutopic endometrium.
With the identification of BCL6 as an endometrial protein
expressed in the secretory phase, we hypothesized that an
endometrial biopsy-based test for endometriosis may be fea-
sible. To address this question, we first compared secretory
endometrium, from laparoscopically proven cases of endome-
triosis to endometrium from fertile women without disease at
laparoscopy. After establishing that the area under the curve
exceeded 50%,36 we proceeded to find an HSCORE cutoff
with the highest likelihood ratio. Next, we applied the test
to a group of prospectively obtained, MS endometrial samples
from women with UI.
We demonstrate that BCL6 positivity was more frequent in
the UI group compared to those with proven normal fertility
(Figure 1F). Of the 65 cases who had laparoscopy, 61 (94%)
had endometriosis, 3 (4.6%) had unsuspected hydrosalpinx,
and 1 was found to be normal. While the incidence of endo-
metriosis predicted by BCL6 expression in women with UI
was high, other laparoscopic studies have suggested a very
high incidence in this population.4-6 Although the population
that underwent laparoscopy due to clinician practice may be
enriched for endometriosis, it is important to note the histor-
ical trend of increasing prevalence of endometriosis in this
population due to improved laparoscopic equipment and a
better appreciation of subtle forms of endometriosis.40 Based
on the findings presented here, we predict further increases in
the reported prevalence of endometriosis as better diagnostic
biomarkers become available. Women with proven fertility
also occasionally tested about the ROC defined cutoff value
of 1.4 (Figure 1F). This may indicate other inflammatory
conditions such as adenomyosis not appreciated at the time
of laparoscopy.
Strengths of our study include a sufficient sample size and
appropriate statistical analysis of normal BCL6 expression
through the normal menstrual cycle. All endometrial samples
were obtained prior to laparoscopy in women with and without
this disorder. Based on power analysis and the differential
staining for BCL6 in women with endometriosis, we had 4
times the number of samples needed to have a 95% chance
of detecting, as significant at the 1% level, an increase in the
primary outcome from 0.4 in the control group to 3.1 HSCORE
in the endometriosis group. Based on ROC analysis, a defined
HSCORE cutoff for BCL6 discriminates between women with
and without this disorder.
Potential limitations include the case–control study
design, which prevents us from properly calculating positive
and negative predictive value. However, these data provide
an HSCORE cutoff for future clinical studies. It is reassuring
that only 7% of the nonlaparoscoped fertile controls tested
positive, since this is similar to the published prevalence in
the general population of 5% to 8%.40 However, even fertile
controls without endometriosis proven by laparoscopy occa-
sionally tested positive for BCL6, even without visible
abnormalities, suggesting other inflammatory abnormalities
might be present (ie, adenomyosis).
The diagnosis of endometriosis by visual inspection, and
not solely by pathology, is a potential bias. Minimal or mild
endometriosis is often treated by laser ablation or cautery,
with no specimen available for pathological confirmation.
Nevertheless, most of our cases (24 of 29) had pathologically
confirmed endometriosis. It is possible that patients selected
for surgery were more likely to have endometriosis. Never-
theless, these data confirm that BCL6-positive cases were
associated with pathologic findings. These data also suggest
that endometriosis is not the only diagnosis associated with
BCL6 positivity. Like integrin testing,41 BCL6 may have a
more global application for diseases that cause inflammation,
rather than just indicating endometriosis.
Figure 2. Representative B-Cell CLL/Lymphoma 6 (BCL6) protein
immunostaining expression in endometrial paraffin sections over the
menstrual cycle. (A) normal proliferative, (B) normal early secretory,
(C) normal mid-secretory, (D) normal late secretory, and (E) endo-
metriosis—mid-secretory. Positive (F) and negative controls (G).
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It is too soon to extrapolate these data to all women with
endometriosis. Future studies will need to be performed on
women without pain, or women with endometriosis but with-
out infertility, to determine whether BCL6 is diagnostic for
endometriosis in this group of women as well. Since endo-
metriosis can exist in infertile women without symptoms, a
biomarker for this population would be of value. In addition,
ongoing studies in animal models are being performed to
determine whether BCL6 is a direct result of endometriosis
lesion establishment and the inflammatory responses gener-
ated by this disease.
Conclusion
Based on both mRNA and protein analysis, we have strong
evidence that BCL6 has low expression in women without
endometriosis. In contrast, it is highly overexpressed in women
with endometriosis during the secretory phase of the menstrual
cycle. The significant difference in BCL6 protein expression
between women with and without endometriosis testing yields
an area under the curve of 94%. A cutoff of 1.4 in HSCORE
provides an likelihood ratio of 15.4 and 0.04 for positive and
negative results, respectively. These results, in conjunction
with clinical signs and symptoms, including infertility, will
need to be applied in prospective trials to determine the diag-
nostic accuracy of BCL6 as a biomarker for endometriosis.
Considering the difficulty in diagnosis of endometriosis or pro-
spectively predicting cases of diminished endometrial receptiv-
ity, a reliable marker for endometriosis and/or reduced
endometrial receptivity would result in a paradigm shift for
both diagnosis and treatment of infertile women.
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